67 related articles for article (PubMed ID: 1462037)
1. [The soluble IL-2 receptor in malignant hemopathies].
Rupoli S; Montillo M; Salvi A; Brianzoni MF; Centurioni R; Cinciripini A; Paoletti P; Recchioni A; Leoni P
Recenti Prog Med; 1992 Oct; 83(10):546-51. PubMed ID: 1462037
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
4. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia.
Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V
Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
[TBL] [Abstract][Full Text] [Related]
7. The soluble interleukin-2 receptor as a marker for human neoplasia and immune status.
Zerler B
Cancer Cells; 1991 Dec; 3(12):471-9. PubMed ID: 1820093
[TBL] [Abstract][Full Text] [Related]
8. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
9. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
[TBL] [Abstract][Full Text] [Related]
10. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
Xu J; Wang B
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
[TBL] [Abstract][Full Text] [Related]
11. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma.
Kalmanti M; Karamolengou K; Dimitriou H; Tosca A; Vlachonikolis I; Peraki M; Georgoulias V; Kalmantis T
Int J Hematol; 1993 Apr; 57(2):147-52. PubMed ID: 8494993
[TBL] [Abstract][Full Text] [Related]
13. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin 2 receptors in patients with malignant lymphoma.
Harrington DS; Patil K; Lai PK; Yasuda NN; Armitage JO; Ip SH; Weisenburger DD; Linder J; Purtilo DT
Arch Pathol Lab Med; 1988 Jun; 112(6):597-601. PubMed ID: 2837161
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
17. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of soluble interleukin-2 receptor (sIL-2R) in B-chronic lymphocytic leukemia.
Cacciola E; Calogero D; Marra G; Guglielmo P
Boll Soc Ital Biol Sper; 1992 Apr; 68(4):259-62. PubMed ID: 1463600
[TBL] [Abstract][Full Text] [Related]
19. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
20. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
